Journal articleHuman

The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection

Nature medicine, 2006 Jun. Chromek M, Slamová Z, Bergman P and 8 others.

Study type

Journal article

Subjects

Human participants (PubMed MeSH: Humans)

Journal

Nature medicine

Published

2006 Jun

PubMed

PMID 16751768 ↗

DOI

10.1038/nm1407 ↗

Where PepCue cites this

This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.

LL-37 →

Indexed under

MeSH terms assigned by the National Library of Medicine.

AnimalsAnti-Infective AgentsAntimicrobial Cationic PeptidesChildDrug Resistance, BacterialEpithelial CellsEscherichia coliEscherichia coli InfectionsHumansImmunity, MucosalKidney CortexMice

Other papers on LL-37

Randomized controlled trial · 2021

Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial

Randomized controlled trial · 2014

Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial

Review · 2016

LL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activity

PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.

Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page